The 4th ADC Analytical Development Summit is returning to Boston in April 2025. This event will bring together the brightest minds in the field to address the unique analytical challenges of antibody-drug conjugates. As regulatory expectations tighten and ADCs become increasingly complex, this summit will serve as your guide to ensuring high-quality products and seamless regulatory submissions.

With the FDA’s updated ICH Q14 guidance raising the bar for release and stability testing, adopting advanced analytical methods is more critical than ever to maintain product quality. This summit offers a unique platform to explore how to meet these regulatory requirements effectively while ensuring your ADC remains robust throughout its lifecycle.

ADC developers are increasingly working with novel payloads, linkers, and next-generation formats, such as multispecific conjugates and antibody-radio conjugates. These advancements introduce unprecedented complexity, requiring tailored analytical strategies to address challenges in DAR quantification, drug distribution analysis, and impurity profiling. This event delves into the methodologies needed to navigate these technical hurdles and adapt to the evolving ADC landscape.

The summit will also explore how cutting-edge analytical tools are being leveraged to enhance bioassays and improve potency measurement, providing deeper insights into ADC mechanisms of action. You’ll gain actionable strategies for refining impurity assays to quantify free drug and process-related impurities-critical for producing high-quality products that meet global regulatory standards.

URLs:

Tickets: https://go.evvnt.com/2838705-0?pid=91 

Brochure: https://go.evvnt.com/2838705-3?pid=91 

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Prices:

Drug Developer - Conference Only: USD 2999.00,

Drug Developer - Conference + Workshop Day: USD 4197.00,

Academic - Conference Only: USD 2599.00,

Academic - Conference + Workshop Day: USD 3597.00,

Solution Provider - Conference Day Only: USD 3699.00,

Solution Provider - Conference + Workshop Day: USD 5097.00

Speakers: Carrie Sowers Associate Director, Physicochemical Development, AstraZeneca, Ece Topuzlu, Principal Scientist, Johnson and Johnson, Hao Luo Associate, Scientific Director, Bristol Myers Squibb, Hui Wei Scientific, Director, Bristol Myers Squibb, Jing Li, Associate Director, Alexion, Kevin Halloran, Senior Scientist, AbbVie, Khyati Shah, Associate Director, Sutro Biopharma, Kishore Hotha, Global Vice President- Lab Operations, Veranova, Lance Cadang, Scientist, Genentech, Meghan O Leary, Senior Scientist Merck, Mei May Zhu, Director, CDMO/ CTO Relationship Management Takeda, Milica Bulajic, Senior Scientist AstraZeneca, Moon Chatterjee, Research Scientist Gilead, Nick Neubacher, Group Leader Bioanalytics Heidelberg Pharma, Olivier Ducoudret, Associate Director MacroGenics, Porsha Howell, Bioassay and Center of Excellence Scientist Bristol Myers Squibb, Renpeng Liu, Principal Scientist Pyxis Oncology, Shiyu zhou, Principal Scientist - Research Abbvie, Sreya Sarkar, Senior Scientist Genentech, Wona Joo, Principal Scientist Johnson and Johnson, Yuan Gao, Head of Analytical Development, ADC Therapeutics, Yuan Ren, Principal Scientist Bristol Myers Squibb